Hypothesis on the possible relevance of the immunogenic cell death in the treatment of gestational trophoblastic neoplasms.

Bystander effect Cancer genome Gestational choriocarcinoma Immunogenic cell death Immunomodulatory chemotherapies

Journal

Translational oncology
ISSN: 1936-5233
Titre abrégé: Transl Oncol
Pays: United States
ID NLM: 101472619

Informations de publication

Date de publication:
Dec 2021
Historique:
received: 01 06 2021
revised: 31 08 2021
accepted: 10 09 2021
pubmed: 1 10 2021
medline: 1 10 2021
entrez: 30 9 2021
Statut: ppublish

Résumé

The genetic background and the antigenic landscape of cancer cells play a critical role in the response to immunotherapies. A high tumor antigenicity, together with an increased adjuvanticity potentially induced by a peculiar type of cell death, namely immunogenic cell death (ICD), could foster the response to immunogenic therapies. The gestational trophoblastic neoplasm (GTN) is a one-of-a-kind cancer in the oncological landscape due to its exclusive genomic makeup. The prognosis of GTN is significantly better than non-gestational trophoblastic neoplasm (nGTN). Due to its peculiar genetic inheritance, GTN potentially constitutes a singular archetype in the immuno-oncological field.

Identifiants

DOI: 10.1016/j.tranon.2021.101224 PMID: 34592590 PMC: PMC8482038
pubmed: 34592590
pii: S1936-5233(21)00216-3
doi: 10.1016/j.tranon.2021.101224
pmc: PMC8482038
pii:
doi:

Types de publication

Journal Article

Langues

eng

Pagination

101224

Informations de copyright

Copyright © 2021. Published by Elsevier Inc.

Auteurs

G Frega (G)

Department of Specialistic, Diagnostic and Experimental Medicine (DIMES), Alma Mater Studiorum, University of Bologna, Italy; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni n.15, 40138 Bologna, Italy. Electronic address: giorgio.frega2@unibo.it.

O Kepp (O)

Equipe labellisée par la Ligue contre le cancer, INSERM UMR1138, Centre de Recherche des Cordeliers, Université de Paris, Sorbonne Université, Paris, France; Metabolomics and Cell Biology Platforms, Gustave Roussy, Villejuif, France.

D Turchetti (D)

Department of Specialistic, Diagnostic and Experimental Medicine (DIMES), Alma Mater Studiorum, University of Bologna, Italy; U.O. Genetica Medica, Policlinico S. Orsola-Malpighi, Centro di Ricerca sui Tumori Ereditari, Bologna Italy.

A Rizzo (A)

Department of Specialistic, Diagnostic and Experimental Medicine (DIMES), Alma Mater Studiorum, University of Bologna, Italy; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni n.15, 40138 Bologna, Italy.

M A Pantaleo (MA)

Department of Specialistic, Diagnostic and Experimental Medicine (DIMES), Alma Mater Studiorum, University of Bologna, Italy; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni n.15, 40138 Bologna, Italy.

G Brandi (G)

Department of Specialistic, Diagnostic and Experimental Medicine (DIMES), Alma Mater Studiorum, University of Bologna, Italy; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni n.15, 40138 Bologna, Italy.

Classifications MeSH